• Loading stock data…

Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Last Updated on September 6, 2022 by GlobeNewsWire

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR(R) platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in a fireside chat and participate virtually in one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference, to be held virtually and in New York, NY from September 12-14, 2022.

H.C. Wainwright 24th Annual Global Investment Conference Format: Pre-recorded fireside chat and one-on-one investor meetingsDate: Monday, September 12, 2022Time: Fireside chat available at 7:00 a.m. ETWebcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR(R) platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:Bruce MackleLifeSci Advisors, LLC+1-929-469-3859bmackle@lifesciadvisors.com

For Media: Brittany Leigh, Ph.D.LifeSci Communications, LLC+1-646-751-4366bleigh@lifescicomms.com

Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: